A phase I dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL999 administered intravenously to subjects with solid tumors
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2015
At a glance
- Drugs XL 999 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 23 Feb 2010 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 23 Feb 2010 Actual initiation date (Nov 2004) and actual patient number (52) added as reported by ClinicalTrials.gov
- 21 Oct 2008 Status changed from active, no longer recruiting to completed.